Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR-Reference-Cited by-同舟云学术

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR

Published:2018-08-27 Issue:11 Volume:9 Page:1398-1405
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Hsia Te-Chun¹²,Liang Ji-An³⁴,Li Chia-Chin³,Chien Chun-Ru³⁴⁵

Affiliation:

1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine; China Medical University Hospital; Taichung Taiwan

2. Department of Respiratory Therapy; China Medical University; Taichung Taiwan

3. Department of Radiation Oncology; China Medical University Hospital; Taichung Taiwan

4. School of Medicine, College of Medicine; China Medical University; Taichung Taiwan

5. Department of Radiation Oncology; China Medical University Hsinchu Hospital; Hsinchu Taiwan

Funder

The Ministry of Science and Technology (MOST)

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12847/fullpdf

Reference39 articles.

1. International Agency for Research on Cancer, World Health Organization https://gco.iarc.fr

2. Recent clinical advances in lung cancer management;Johnson;J Clin Oncol,2014

3. National Comprehensive Cancer Network (NCCN) 2017 https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

4. How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?;Bayman;Lung Cancer,2014

5. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors;Canadian Respiratory Journal;2024-03-05

2. Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer;Aging;2024-01-11

3. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives;Lung Cancer;2024-01

4. A novel long noncoding RNA (lncRNA), LINC02657(LASTR), is a prognostic biomarker associated with immune infiltrates of lung adenocarcinoma based on unsupervised cluster analysis;PeerJ;2023-11-28

5. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer;Expert Review of Anticancer Therapy;2023-08-13